Otwarty dostęp

High Expression of CIP2A Can Promote the Proliferation, Migration, and Epithelial-Mesenchymal Transition of Diffuse Large B-Cell Lymphoma Cells

Caifang Zhao

Caifang Zhao

Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of MedicineJinhua, China
Wyszukaj tego autora
Sciendo|Google Scholar
Zhao, Caifang
, 
Xiang Weng

Xiang Weng

Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of MedicineJinhua, China
Wyszukaj tego autora
Sciendo|Google Scholar
Weng, Xiang
, 
Wei He

Wei He

Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of MedicineJinhua, China
Wyszukaj tego autora
Sciendo|Google Scholar
He, Wei
 oraz 
Yanming Lei

Yanming Lei

Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of MedicineJinhua, China
Wyszukaj tego autora
Sciendo|Google Scholar
Lei, Yanming
  
29 maj 2025
High Expression of CIP2A Can Promote the Proliferation, Migration, and Epithelial-Mesenchymal Transition of Diffuse Large B-Cell Lymphoma Cells's Cover Image
O artykule
Poprzedni artykuł
Następny artykuł
Zacytuj
Pobierz okładkę
Data publikacji: 29 maj 2025
Otrzymano: 07 lut 2025
Przyjęty: 07 kwi 2025
DOI: https://doi.org/10.2478/aite-2025-0016
Słowa kluczowe
© 2025 Caifang Zhao et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Fig 1.

CIP2A exhibited higher expression in DLBC. (A) The expression of CIP2A was verified in normal tissues or DLBC tissues from GEPIA online database. (B) The protein expression of CIP2A was examined in normal tissues (n=10) and DLBC tissues (n=10) through western blot. (C) The protein expression of CIP2A was measured in normal human B lymphocyte (GM12878) and DLBC cell lines (SU-DHL-4, SU-DHL-6 and SU-DHL-10). *p<0.05, ***p<0.001.
CIP2A exhibited higher expression in DLBC. (A) The expression of CIP2A was verified in normal tissues or DLBC tissues from GEPIA online database. (B) The protein expression of CIP2A was examined in normal tissues (n=10) and DLBC tissues (n=10) through western blot. (C) The protein expression of CIP2A was measured in normal human B lymphocyte (GM12878) and DLBC cell lines (SU-DHL-4, SU-DHL-6 and SU-DHL-10). *p<0.05, ***p<0.001.

Fig 2.

Inhibition of CIP2A restrained cell growth and metastasis in DLBC. Groups were separated into the Control, shNC, and shCIP2A. (1A, B) The protein expression of CIP2A was determined through western blot. (1C) The cell survival was confirmed through CCK-8 assay. (1D) The cell proliferation was inspected through colony formation assay. (1E) The cell migration and invasion were measured through transwell assay. ***p < 0.001. (2A) The Ki67 protein expression was examined through IF assay. (2B, C) The cell cycle was evaluated through flow cytometry. ***p < 0.001. CIP2A, cancerous inhibitor of protein phosphatase 2A; DLBC, diffuse large B-cell lymphoma; shNC, short hairpin negative control.
Inhibition of CIP2A restrained cell growth and metastasis in DLBC. Groups were separated into the Control, shNC, and shCIP2A. (1A, B) The protein expression of CIP2A was determined through western blot. (1C) The cell survival was confirmed through CCK-8 assay. (1D) The cell proliferation was inspected through colony formation assay. (1E) The cell migration and invasion were measured through transwell assay. ***p < 0.001. (2A) The Ki67 protein expression was examined through IF assay. (2B, C) The cell cycle was evaluated through flow cytometry. ***p < 0.001. CIP2A, cancerous inhibitor of protein phosphatase 2A; DLBC, diffuse large B-cell lymphoma; shNC, short hairpin negative control.

Fig 3.

Knockdown of CIP2A repressed EMT progress in DLBC. Groups were separated into the Control, shNC, and shCIP2A. The protein expressions of E-cadherin, N-cadherin, and α-SMA were evaluated through western blot. ***p < 0.001. CIP2A, cancerous inhibitor of protein phosphatase 2A; DLBC, diffuse large B-cell lymphoma; EMT, epithelial-mesenchymal transition; shNC, short hairpin negative control.
Knockdown of CIP2A repressed EMT progress in DLBC. Groups were separated into the Control, shNC, and shCIP2A. The protein expressions of E-cadherin, N-cadherin, and α-SMA were evaluated through western blot. ***p < 0.001. CIP2A, cancerous inhibitor of protein phosphatase 2A; DLBC, diffuse large B-cell lymphoma; EMT, epithelial-mesenchymal transition; shNC, short hairpin negative control.

Fig 4.

Suppression of CIP2A retarded the Wnt/β-catenin pathway. Groups were separated into the Control, shNC, and shCIP2A. The protein expressions of β-catenin, c-Myc, and cyclin D1 were inspected through western blot. ***p < 0.001. CIP2A, cancerous inhibitor of protein phosphatase 2A; shNC, short hairpin negative control.
Suppression of CIP2A retarded the Wnt/β-catenin pathway. Groups were separated into the Control, shNC, and shCIP2A. The protein expressions of β-catenin, c-Myc, and cyclin D1 were inspected through western blot. ***p < 0.001. CIP2A, cancerous inhibitor of protein phosphatase 2A; shNC, short hairpin negative control.
Język:
Angielski
Częstotliwość wydawania:
1 razy w roku
Dziedziny czasopisma:
Medycyna, Podstawowe nauki medyczne, Biochemia, Immunologia, Medycyna kliniczna, Medycyna kliniczna, inne, Chemia kliniczna
Kanał RSS czasopisma